The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Combining low-dose regorafenib with pembrolizumab for patients with MSI-H colorectal cancer: REGPEM-CRC-01.
 
Ibrahim Halil Sahin
Consulting or Advisory Role - GlaxoSmithKline
 
Sakti Chakrabarti
Honoraria - BioMedical Insights; Cancer Expert Now; HalioDx; Histosonics; Natera; omnihealth Media; QED Therapeutics
Speakers' Bureau - Bristol Myers Squibb; Merck; Natera; Seagen
(OPTIONAL) Uncompensated Relationships - Binacea
 
Ronan Wenhan Hsieh
No Relationships to Disclose
 
Tullia C. Bruno
No Relationships to Disclose
 
Jennifer Eva Selfridge
No Relationships to Disclose
 
Vikram Gorantla
No Relationships to Disclose
 
Roby Antony Thomas
No Relationships to Disclose
 
John C. Rhee
No Relationships to Disclose
 
Curtis Tatsuoka
No Relationships to Disclose
 
David L. Bajor
Employment - University Hospitals Case Medical Center
Stock and Other Ownership Interests - Mirati Therapeutics
Consulting or Advisory Role - Guidepoint Global
Speakers' Bureau - Natera
Research Funding - Abbvie; Apexigen (Inst); Bristol-Myers Squibb/Celgene (Inst); Calithera Biosciences (Inst); GlaxoSmithKline (Inst); Rafael Pharmaceuticals (Inst); Seagen (Inst); Tesaro (Inst)
 
Amit Mahipal
No Relationships to Disclose
 
E. Gabriela Chiorean
Consulting or Advisory Role - Astellas Pharma; Axiom Healthcare Strategies; Bayer; Bristol-Myers Squibb/Celgene; Cardiff Oncology; Foundation Medicine; G1 Therapeutics; IgM Biosciences; Ipsen; Merck; Merus; Novartis; Pfizer; Stemline Therapeutics
Research Funding - AADi (Inst); BioMed Valley Discoveries (Inst); Boehringer Ingelheim (Inst); Erasca, Inc; FibroGen (Inst); Gilead/Forty Seven; Lonza (Inst); Merck (Inst); Novartis; Rafael Pharmaceuticals (Inst); Roche (Inst); Stemline Therapeutics (Inst)
Travel, Accommodations, Expenses - G1 Therapeutics
 
Mohamedtaki Abdulaziz Tejani
Consulting or Advisory Role - Exelixis
Speakers' Bureau - Natera
Research Funding - Bayer (Inst)
 
Anwaar Saeed
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Exelixis; Five Prime Therapeutics; Pfizer
Research Funding - Actuate Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo/UCB Japan (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); innovent biologics (Inst); KAHR Medical (Inst); Merck Sharp & Dohme (Inst); Seagen (Inst)